GLP-1RAs significantly reduce weight, blood pressure, and glucose in overweight/obese Chinese adults
Background
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown considerable efficacy for weight loss and metabolic improvement globally, their specific cardio-metabolic benefits and safety in overweight or obese Chinese adults have not been comprehensively characterized. This demographic faces unique challenges in managing obesity and associated cardio-metabolic risk factors, including type 2 diabetes, hypertension, and dyslipidemia. Understanding the precise impact of GLP-1RAs in this population is crucial for guiding clinical practice and optimizing therapeutic strategies, addressing a key gap in regional evidence.
Study Design
Researchers conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GLP-1RAs or dual GLP-1/GIP receptor agonists against placebo in overweight or obese Chinese adults. Searches spanned PubMed, Cochrane CENTRAL, and Scopus up to October 2025. The analysis included five RCTs with a total of 2,204 participants, where 1,522 received GLP-1RA therapy and 682 received placebo. Primary endpoints included changes in body weight, waist circumference, HbA1c, fasting glucose, cholesterol, systolic and diastolic blood pressure, and adverse events. Effect sizes were pooled using random-effects models.
Results
GLP-1RAs demonstrated clinically significant improvements across multiple cardio-metabolic parameters. They significantly reduced body weight by a mean difference (MD) of -10.06 kg (95% CI: -15.56 to -4.56), and waist circumference by -7.06 cm (95% CI: -9.85 to -4.26). Glycemic control also improved, with HbA1c decreasing by -0.41% (95% CI: -0.56 to -0.27) and fasting glucose by -0.48 mmol/L (95% CI: -0.69 to -0.27). Lipid profiles saw a reduction in cholesterol by -7.95 mg/dL (95% CI: -9.57 to -6.33). Blood pressure also improved, with systolic blood pressure (SBP) dropping by -4.26 mmHg (95% CI: -6.28 to -2.23) and diastolic blood pressure (DBP) by -2.44 mmHg (95% CI: -3.70 to -1.18).
Key Findings
- GLP-1RAs reduced body weight by -10.06 kg (95% CI: -15.56 to -4.56) in overweight/obese Chinese adults.
- Waist circumference decreased by -7.06 cm (95% CI: -9.85 to -4.26).
- HbA1c was lowered by -0.41% (95% CI: -0.56 to -0.27), and fasting glucose by -0.48 mmol/L.
- Cholesterol levels dropped by -7.95 mg/dL (95% CI: -9.57 to -6.33).
- Systolic blood pressure decreased by -4.26 mmHg and diastolic blood pressure by -2.44 mmHg.
Why It Matters
This meta-analysis provides robust evidence supporting the use of GLP-1RAs for comprehensive cardio-metabolic risk reduction in overweight or obese Chinese adults. Clinicians can now more confidently prescribe GLP-1RAs in this specific population, knowing they offer substantial benefits beyond just weight loss, including improvements in blood glucose, lipids, and blood pressure. This expands the evidence base for personalized medicine, affirming GLP-1RAs as effective long-term therapeutic options. While specific dosing protocols were not detailed in this meta-analysis, the overall class effect suggests a strong foundation for integrating these agents into existing treatment algorithms for metabolic syndrome and obesity management in Chinese patients.
glp-1ra
obesity
overweight
chinese-adults
meta-analysis
cardiovascular-health